
    
      CD19-UCART is a kind of "off-the-shelf" product originated from health donor's PBMC.This is a
      open-label, dose estilation study to evaluate the safety and anti-tumor efficacy of
      CD19-UCART in the treatment of relapsed or refractory B-cell hematological malignancies.
    
  